Roadshow
PB103
Precision Biotech independently developed an immune cell product, PB103, to achieve the high purity of NK cells for allogenic use. Our enrichment technology is efficiently prepared from peripheral blood without the use of any magnetic beads and in vitro amplification by our unique patented method.
Precision Biotech independently developed an immune cell product, PB103, to achieve the high purity of NK cells for allogenic use. Our enrichment technology is efficiently prepared from peripheral blood without the use of any magnetic beads and in vitro amplification by our unique patented method.
PB103 technology demonstrated the ability to increase the amount of NK cells to ten thousands fold with over 95% viability, 90% positivity with CD16/CD314 cells and high efficiency of cytotoxicity in cancer cell (80% killing effect).
PB103 is the first clinical trial for allogenic immune cell therapy that is approved by TFDA in Taiwan and supported by A industrial innovative R&D program. Our goal is to find an alternative method to transform medicine with our novel NK cell-based therapies to be a standard of care for cancer patients by clinical evidence in the asian-pacific region.
- Established 2017
- Company Precision Biotech
- Telephone ＋886-2-85210148
- Address 16F, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City 115011, Taiwan
Founded in Dec. 2017, Precision Biotech Taiwan Corp. is a clinical stage immune cell therapy company that develops next-generation therapy to combat cancers and infectious diseases. Our therapy focuses on using NK, NKT, CIK, DC-CIK and MSC cell technology for applications. Our product PB101(autologous use) and PB103 (allogeneic use) have been approved by TFDA for clinical trial administration in lung cancer patients. 2021, our team has been approved to set up a R&D center in Hong Kong Science and Technology Park to collaborate with multiple research centers in other countries for clinical interests, including CAR-NK (a next generation NK cell technology). Our vision is to create innovative immunotherapies that can help address serious unmet needs in oncology.